New Medication in Diabetes Treatment (S1/#2)
People living with diabetes, in particular people with Type 1 Diabetes (T1D), there are still Glycaemia unmet needs: insufficient glycaemic control; risk of severe hypoglycaemia; weight gain; glucose variability. The impact of all of these on the quality of life and the chronic complications of diabetes luring around the corner, thus putting the burden of the day to day glycaemia management on the individual.
Solutions that may help to deal better with the aforementioned needs:
1. Injectable Glucagon
2. Nasal Glucagon for severe Hypoglycaemia
3. Adjunct therapies: GLP1 Receptor Agonists
4. Adjunct therapies: SGLT2 inhibitors
SGLT2 inhibitors can be prescribed to someone with T1D who is an Adult; following instructions; with lower HbA1c (9-10%); having higher enough doses of insulin- >20units/day; and following European Medicines Agency (EMA) having BMI >27kg/m² and most importantly EDUCATION! EDUCATION! EDUCATION!
Patient Education: on how to avoid Diabetic Ketoacidosis and what to do in case of ketones
Clinical Education: all prescribing clinicians should acquire full understanding of the safe use & risks associated with SGLT-inhibitor therapy (on how to detect ketones in individuals with T1D on SGLT-inhibitors and what to do in case of a threat of Diabetic ketoacidosis).